Caprotec Raises $5.1M to Apply Capture Compound Mass Spec Technology to Drug Development
May 21, 2010
Caprotec Raises $5.1M to Apply Capture Compound Mass Spec Technology to Drug Development
The technology, which enables the isolation of functionally selected proteins from complex biological samples, has demonstrated potential usefulness in studying drug-protein interactions and could increase the efficiency of the drug development process.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Caprotec Touts Success of CCMS Technology in Drug Development Study with Roche
July 2, 2010 / ProteoMonitor - Big Pharma Exploring Targeted MS to Measure Key Transporter Proteins for Drug Development
August 12, 2011 / ProteoMonitor - Merck To Use Morphosys' HuCAL Gold Antibodies in Vaccine Research
August 5, 2011 / ProteoMonitor - BGI Aims to Expand Proteomics Services, Purchase 50-Plus New Mass Spectrometers
June 17, 2011 / ProteoMonitor - Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor